RAQUEL
RIVERA DÍAZ
Profesora asociada de Ciencias de la Salud
![Foto de RAQUEL](/img/nophoto.png)
![Foto de Hospital Universitario de la Princesa](/img/noimage_org.png)
Hospital Universitario de la Princesa
Madrid, EspañaPublications en collaboration avec des chercheurs de Hospital Universitario de la Princesa (48)
2024
-
Family Planning Concerns Among Women With Psoriasis: A Descriptive, Cross-Sectional, Multicenter Study
Actas Dermo-Sifiliograficas, Vol. 115, Núm. 1, pp. 10-20
-
Psoriasis Severity, Health-Related Quality of Life, Work Productivity, and Activity Impairments Among Patients With Moderate to Severe Psoriasis Receiving Systemic Treatment: Real-World Data From Clinical Practice in Spain
Actas Dermo-Sifiliograficas, Vol. 115, Núm. 1, pp. 1-9
-
Real-world Safety and Efficacy of Risankizumab in Psoriatic Patients: A Multicenter, Retrospective, and Not-interventional Study
Actas Dermo-Sifiliograficas
2023
-
Apremilast treatment of plaque psoriasis (PsO) after systemic therapy in Spanish clinical practice: Data from the APPROPRIATE study
JEADV Clinical Practice, Vol. 2, Núm. 3, pp. 488-501
-
Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group
Journal of the European Academy of Dermatology and Venereology, Vol. 37, Núm. 12, pp. 2517-2525
-
Efficacy and Safety of Dimethyl Fumarate in Patients with Moderate-to-Severe Plaque Psoriasis: Results from a 52-Week Open-Label Phase IV Clinical Trial (DIMESKIN 1)
Dermatology and Therapy, Vol. 13, Núm. 1, pp. 329-345
-
High adherence to secukinumab in patients with moderate to severe psoriasis: a long-term multicenter study in a daily practice setting
International Journal of Dermatology
-
Tildrakizumab improves high burden skin symptoms, impaired sleep and quality of life of moderate-to-severe plaque psoriasis patients in conditions close to clinical practice
Journal of the European Academy of Dermatology and Venereology, Vol. 37, Núm. 10, pp. 2004-2015
2022
-
Differences in epidemiology, comorbidities and treatment choice between plaque psoriasis and pustular psoriasis: results from the BIOBADADERM registry
British Journal of Dermatology
-
Drug survival of adalimumab biosimilars in real-world treatment of psoriasis: A Spanish multicenter study
Dermatologic Therapy
-
Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group
Dermatologic Therapy, Vol. 35, Núm. 2
-
Fast and sustained improvement of patient-reported outcomes in psoriatic patients treated with secukinumab in a daily practice setting
Dermatologic Therapy, Vol. 35, Núm. 8
-
Risankizumab in psoriasis: prior biologics failure does not impact on short-term effectiveness
Expert Opinion on Biological Therapy
-
Secukinumab is effective and safe in the long-term treatment of plaque psoriasis in a daily practice setting: Multicenter study in 384 Spanish patients
Dermatologic Therapy, Vol. 35, Núm. 12
-
The risk of hepatic adverse events of systemic medications for psoriasis: a prospective cohort study using the BIOBADADERM registry
Journal of Dermatological Treatment, Vol. 33, Núm. 4, pp. 2110-2117
-
Ustekinumab to guselkumab transitions: A series of 54 patients emulating the navigate trial in real life
Dermatologic Therapy, Vol. 35, Núm. 10
-
Women with moderate-to-severe psoriasis in Spain (BIOBADADERM registry) breastfeed less when compared with general population
Journal of the European Academy of Dermatology and Venereology
2021
-
Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: A Biobadaderm cohort analysis
Journal of the American Academy of Dermatology, Vol. 84, Núm. 2, pp. 513-517
-
Multicenter Retrospective Study of Secukinumab Drug Survival in Psoriasis Patients in a Daily Practice Setting: A Long-Term Experience in Spain
Dermatology and Therapy, Vol. 11, Núm. 6, pp. 2207-2215
2020
-
A retrospective, observational multicenter study of 141 patients treated with ustekinumab 90 mg
Dermatologic Therapy, Vol. 33, Núm. 4